For reprints of publications, please contact Prof. C. Daniel Mullins at: dmullins@rx.umaryland.edu.

Publications By Year

2014 2013 2012 2011 2010 2009

2008 2007 2006 2005 2004 2003

2002 2001 2000 1999 1998 1997

1996 1995 1994

2014

Return to top

    1. Mullins CD, Vandigo J, Zheng Z, Wicks P. Patient-centeredness in the design of clinical trials. Value in Health 2014; forthcoming. [Pubmed] [Open Access Full Text]
    2. Yong C, Onukwugha E, Mullins CD, Seal B, Hussain A. The Use of Health Services among Elderly Patients with Stage IV Prostate Cancer in the Initial Period following Diagnosis. Journal of Geriatric Oncology 2014; forthcoming.
    3. Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-Related Events and Mortality Among Older Men with Advanced Prostate Cancer. Journal of Geriatric Oncology 2014; forthcoming.
    4. Zheng Z Hanna H, Onukwugha E Reese ES, Seal B, Mullins CD. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Medicine 2014; forthcoming.
    5. Onukwugha E, Yong C, Hussain A, Seal B, Mullins CD. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. BMC Medical Research Methodology 2014; forthcoming.
    6. Chirikov VV, Mullins CD, Hanna N, Breunig IM, Seal B, Shaya FT. Multispecialist care and mortality in hepatocellular carcinoma. American Journal of Clinical Oncology 2014; forthcoming.
    7. Bikov KA, Mullins CD, Seal B, Onukwugha E, Hanna N. Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare. Medical Care 2014; forthcoming.
    8. Yong C, Onukwugha E, Mullins CD. Clinical and Economic Burden of Bone Metastasis and Skeletal-Related Events in Prostate Cancer. Current Opinion in Oncology 2014; forthcoming.
    9. Lavallee DC, Wicks P, Alfonso Cristancho R, Mullins CD. Stakeholder Engagement in Patient-Centered Outcomes Research: High-Touch or High-Tech? Expert Review of Pharmacoeconomics & Outcomes Research 2014; 14(3):335-44.
    10. Berger ML, Martin BD, Husereau D, Worley K, Allen JD, Quon NC, Mullins CD, Kahler KH, Crown W. A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health 2014; 17(2):143-56.
    11. Johnson W, Shaya FT, Winston R, Laird CD, Chirikov VV, Saunders E. Diabetes Control Through an Educational Intervention. Ethnicity & Disease 2014; 24(2):182-8.
    12. Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with prostate cancer. Pharmacoeconomics 2014; 32(2)173-91.
    13. Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare. PharmacoEconomics 2014; 32(1):63-74.
    14. Zheng Z, Hanna N, Onukwugha E, Bikov KA, Mullins CD. Hospital Center Effect for Laparoscopic Colectomy Among Elderly Stage I-III Colon Cancer Patients. Annals of Surgery 2014; 259(5):924-9.
    15. Buzaglo J, Gayer C, Mallick R, Charap E, Ferris A, Golant M, Langer C, Morris A, Mullins CD, Cella D. Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study. The Journal of Community and Supportive Oncology 2014; 12(1):6-12.

 

2013

Return to top

    1. Reese ES, Onukwugha E, Hanna N, Seal BS, Mullins CD. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Medicine 2013; 2(6):907-15.
    2. Mullins CD, Yang HK, Onukwugha E, Eisenberg DF, Myers DE, Huang DB, Lodise TP. Rehospitalizations and Direct Medical Costs for cSSSI: Linezolid Versus Vancomycin. The American Journal of Pharmacy Benefits 2013; 5(6):258-67.
    3. Mitikiri ND, Reese ES, Hussain A, Onukwugha E, Pritchard D, Dubois R, Mullins CD. The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. Journal of Comparative Effectiveness Research 2013; 2(6):605-18.
    4. Sonnad SS, Mullins CD, Whicher D, Goldsack J, Mohr PE, Tunis SR. Recommendations for the Design of Phase 3 Pharmaceutical Trials that are more Informative for Patients, Clinicians, and Payers. Contemporary Clinical Trials 2013; 36(2):356-61.
    5. Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clinical Trials 2013; 10(5):807-27.
    6. Ratner J, Mullins CD, Buesching DP, Cantrell RA. Pragmatic Clinical Trials: US Payers’ Views on Their Value. The American Journal of Managed Care 2013; 19(5):e158-e165.
    7. Kauffman KS, dosReis S, Ross M, Barnet B, Onukwugha E, Mullins CD. Engaging hard-to-reach patients in patient-centered outcomes research. Journal of Comparative Effectiveness Research 2013; 2(3):313-24.
    8. Mullins CD, Jain R, Weir MR, Franey CS, Shih YC, Pradel FG, Bikov K, Bartlett ST. Benefits Improvement and Protection Act’s Impact on Transplantation Rates Among Elderly Medicare Beneficiaries with End-Stage Renal Disease. Transplantation 2013; 15;95(3):463-9.
    9. Shaya FT, Chirikov VV, Mullins CD, Shematek J, Howard D, Foster C, Saunders E. Social Networks Help Control Hypertension. The Journal of Clinical Hypertension 2013; 15(1):34-40.
    10. Hung A, Mullins CD. Relative Effectiveness and Safety of Chemotherapy in Elderly and Nonelderly Patients with Stage III Colon Cancer: A Systematic review. The Oncologist 2013; 18(1):54-63.
    11. Johnston SS, Juday T, Seekins D, Hebden T, Fulcher N, Farr AM, Chu BC, Mullins CD. Patterns and Correlates of Linkage to Appropriate HIV Care After HIV Diagnosis in the US Medicaid Population. Sexually Transmitted Diseases 2013; 40(1):18-25.

 

2012

Return to top

    1. Willke RJ, Zheng Z, Subedi P, Althin R, Mullins CD. From concepts, theory and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Medical Research Methodology 2012; 12:185.
    2. Rattinger GB, Mullins CD, Zuckerman IH, Onukwugha E, Walker LD, Gundlapalli A, Samore M, DeLisle S. A Sustainable Strategy to Prevent Misuse of Antibiotics for Acute Respiratory Infections. PLoS ONE 2012; 7(12):e51147.
    3. Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S. Recommendations for Incorporating Patient-Reported Outcomes into Clinical Comparative Effectiveness Research in Adult Oncology. Journal of Clinical Oncology 2012; 30(34):4249-55.
    4. Onukwugha E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Loh FE, Weir MR. A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting. BMJ Open 2012; 2(4):e000902.
    5. Hanna N, Bikov KA, McNally D, Onwudiwe NC, Dalal M, Mullins CD. Impact of Venous Thromboembolism on Mortality of Elderly Medicare Patients with Stage III Colon Cancer. The Oncologist 2012; 17(9):1191-7.
    6. Mullins CD, Dunn JD. Applying Oncology Formulary and Benefit Design Innovations to the Management of Multiple Myeloma in the Managed Care Setting. Journal of Managed Care Pharmacy 2012; 18(8-a):S13-9.
    7. Manabe YC, Hermans SM, Lamorde M, Castelnuovo B, Mullins CD, Kuznik A. Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness analysis. PLoS ONE 2012; 7(6):e39187.
    8. Hsiao FY, Mullins CD, Huang WF. Economic Evaluation of Thiazolidinediones as Add-on Therapy for Treatment of Type 2 Diabetic Patients in the Taiwanese National Health Insurance System. Journal of Food and Drug Analysis 2012; 20(2):1-7.
    9. Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N. Comparative and Cost-Effectiveness of Oxaliplatin-based or Irinotecan-based Regimens Compared with 5-Fluorouracil/Leucovorin Alone Among US Elderly Stage IV Colon Cancer Patients. Cancer 2012; 118(12):3173-81.
    10. Reese E, Mullins CD, Beitelshees AL, Onukwugha E. Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel. Pharmacotherapy 2012; 32(4):323-32.
    11. Rapp T, Andrieu S, Molinier L, Grand A, Cantet C, Mullins CD, Vellas B. Exploring the Relationship between Alzheimer’s Disease Severity and Longitudinal Costs Value in Health 2012; 15(3):412-9.
    12. Mullins CD, Abdulhalim AM, Lavallee DC. Continuous Patient Engagement in Comparative Effectiveness Research. JAMA 2012; 307(15): 1587-8.
    13. Mullins CD, Montgomery R, Abernethy AP, Hussain A, Pearson SD, Tunis S. Recommendations for Clinical Trials of Off-Label Drugs Used to Treat Advanced-Stage Cancer. Journal of Clinical Oncology 2012; 30(6):661-6.
    14. Mullins CD, Shaya FT, Blatt L, Saunders E. A Qualitative Evaluation of a Citywide Community Health Partnership Program. Journal of the National Medical Association 2012; 104(1 and 2):53-60.
    15. Hanna NN, Onukwugha E, Choti MA, Davidoff AJ, Zuckerman IH, Hsu VD, Mullins CD. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using Surveillance, Epidemiology and End Results (SEER)-Medicare data. Colorectal Disease 2012; 14(1):48-55.
    16. Jain R, Mullins CD, Lee H, Wong W. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. Research in Social and Administrative Pharmacy 2012; 8(1):47-59.

 

2011

Return to top

    1. Willke RJ, Mullins CD. “Ten Commandments” for Conducting Comparative Effectiveness Research Using “Real-World Data.” Journal of Managed Care Pharmacy 2011; 17(9 Suppl A):S10-5.
    2. Sanchez RJ, Mardekian J, Cziraky MJ, Mullins CD. Developing a Collaborative Study Protocol for Combining Payer-Specific Data and Clinical Trials for CER. Journal of Managed Care Pharmacy 2011; 17(9 Suppl A):S34-7.
    3. Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW. Relationship between Cardiovascular Outcomes and Proton Pump Inhibitor Use in Patients Receiving Dual Antiplatelet Therapy after Acute Coronary Syndrome. Pharmacoepidemiology and Drug Safety 2011; 20(10):1043-9.
    4. Mullins CD, Ratner J, Ball DE. How Do US Payers React to and Use Pharmacoeconomic Information? International Journal of the Economics of Business 2011; 18(2):317-30.
    5. Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD. The Value of Atorvastatin over the Product Life Cycle in the United States. Clinical Therapeutics. 2011; 33(10):1433-43.
    6. Ezeugwu CO, Laird A, Mullins CD, Saluja DS, Winston RA. Lessons Learned from Community-Based Minority Health Care Serving System Participation in an NIH Clinical Trial. Journal of the National Medical Association 2011; 103(9 and 10):839-44.
    7. Hsiao FY, Mullins CD, Onukwugha E, Pandya N, Hanna N. Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A “Real World” Analysis Using Surveillance, Epidemiology, and End Results–Medicare Data. Journal of the American Geriatrics Society 2011; 59(9):1717-23.
    8. Johnson W, Shaya F, Khanna N, Warrington VO, Rose VA, Yan X, Bailey-Weaver B, Mullins CD, Saunders E. The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): A Randomized Trial of the Effect of Education on Improving Blood Pressure Control in a Largely African-American Population. The Journal of Clinical Hypertension 2011; 13(8):563-70.
    9. Wang J, Liu X, Mullins CD. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Current Medical Research and Opinion 2011; 27(7):1303-13.
    10. Grabner M, Onukwugha E, Jain R, Mullins CD. Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. Co-published as The American Journal of Managed Care. 2011; 17(5 Spec No.):e151-e159; Journal of Oncology Practice 7(3 Suppl):e16s-24s.
    11. Onukwugha E, Mullins CD, Hsu VD, Seal B, Hussain A. Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology 2011; 77(5):1088-95.
    12. Schneider M, Zuckerman IH, Onukwugha E, Pandya N, Seal B, Gardner J, Mullins CD. Chemotherapy Treatment and Survival in Older Women with Estrogen Receptor-Negative Metastatic Breast Cancer: A Population-Based Analysis. Journal of the American Geriatrics Society 2011; 59(4):637-46.
    13. Onukwugha E, Mullins CD, Loh FE, Saunders E, Shaya FT, Weir MR. Readmissions after unauthorized discharges in the cardiovascular setting. Medical Care 2011; 49(2):215-24.
    14. Bradley-Baker LR, Mullins CD, Baquet CR. Pharmacists’ Assessment of Facets of Health Literacy in Pharmacy Practice Settings. Journal of Pharmacy Technology 2011; 27:55-62.
    15. Onwudiwe NC, Mullins CD, Winston RA, Shaya FT, Pradel FG, Laird A, Saunders E. Barriers to Self-Management of Diabetes: A Qualitative Study among Low-Income Minority Diabetics. Ethnicity & Disease 2011; 21(1):27-32.
    16. Mullins CD, Hsu VD, Cooke CE, Shelbaya A, Wallace AE, Perencevich EN. Rehospitalization Rates among Linezolid vs. Vancomycin Users. The American Journal of Pharmacy Benefits 2011; 3(2):e1-e13.

 

2010

Return to top

    1. Mullins CD, Onukwugha E, Cooke JL, Hussain A, Baquet CR. The Potential Impact of Comparative Effectiveness Research on the Health of Minority Populations. Health Affairs 2010; 29(11):2098-104.
    2. Valluri S, Zito JM, Safer DJ, Zuckerman IH, Mullins CD, Korelitz JJ. Impact of the 2004 Food and Drug Administration Pediatric Suicidality Warning on Antidepressant and Psychotherapy Treatment for New-Onset Depression. Medical Care 2010; 48(11):947-54.
    3. Valluri S, Lyons B, Mullins CD. Impact of Food and Drug Administration (FDA) Paediatric Antidepressant Warnings on Stock Prices of Pharmaceutical Manufacturers. Journal of Pharmaceutical Health Services Research 2010; 61-7.
    4. Mullins CD, Whicher D, Reese E, Tunis S. Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials. PharmacoEconomics 2010; 28(10):969-76.
    5. Bollinger ME, Morphew T, Mullins CD. The Breathmobile Program: A Good Investment for Underserved Children with Asthma. Annals of Allergy, Asthma & Immunology 2010; 105(4):274-281.
    6. Rattinger GB, Mullins CD, Zuckerman IH, Onukwugha E, DeLisle S. Clinic Visits and Prescribing Patterns Among Veterans Affairs Maryland Health Care System Dementia Patients. The Journal of Nutrition Health and Aging 2010; 14(8):677-83.
    7. Onukwugha E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Weir MR. Reasons for discharges against medical advice: a qualitative study. Quality and Safety in Health Care 2010; 19(5):420-4.
    8. Mullins CD, Onukwugha E, Bikov K, Seal B, Hussain A. Health Disparities in Staging of SEER-Medicare Prostate Cancer Patients in the United States. Urology 2010; 76(3):566-72.
    9. Wang J, Mullins CD, Chang CF, Gourley DR, Shih YT, Cushman WC, Dagogo-Jack S, White-Means SI. Comparisons of changes over time in per capita health expenditures across racial and ethnic groups. International Journal of Public Policy 2010; 6(3/4):172-89.
    10. Obeidat NA, Pradel FG, Zuckerman IH, Trovato JA, Palumbo FB, DeLisle S, Mullins CD. Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer. The American Journal of Managed Care 2010; 16(7):515-522.
    11. Margolis JM, Cao Z, Onukwugha E, Sanchez RJ, Alvir J, Joshi AV, Mullins CD. Healthcare Utilization and Cost Effects of Prior Authorization for Pregabalin in Commercial Health Plans. The American Journal of Managed Care 2010; 16(6):447-56.
    12. Wang J, Mullins CD, Brown LM, Shih YT, Dagogo-Jack S, Hong SH, Cushman WC. Disparity Implications of Medicare Eligibility Criteria for Medication Therapy Management Services. Health Services Research 2010; 45(4):1061-82.
    13. Barnet B, Rapp T, DeVoe M, Mullins CD. Cost-effectiveness of a Motivational Intervention to Reduce Rapid Repeated Childbearing in High-Risk Adolescent Mothers: A Rebirth of Economic and Policy Considerations. Archives of Pediatrics & Adolescent Medicine 2010; 164(4):370-6.
    14. Mullins CD, Montgomery R, Tunis S. Uncertainty in Assessing Value of Oncology Treatments. The Oncologist 2010; 15(suppl 1):58-64.
    15. Bridges JF, Onukwugha E, Mullins CD. Healthcare Rationing by Proxy: Cost-Effectiveness Analysis and the Misuse of the $50,000 Threshold in the US. Pharmacoeconomics 2010; 28(3):175-84.
    16. Hsiao FY, Mullins CD. The Association between Thiazolidinediones and Hospitalisation for Fracture in Type 2 Diabetic Patients: A Taiwanese Population-Based Nested Case-Control Study. Diabetologia 2010; 53(3):489-96.
    17. Belletti D, Zacker C, Mullins CD. Perspectives on electronic medical records adoption: electronic medical records (EMR) in outcomes research. Patient Related Outcome Measures 2010; 1:29-37.
    18. Palumbo FB, Simoni-Wastila L, Lavallee DC, Blatt L, Mullins CD. Access to Pharmaceuticals in the Post-Medicare Part D Era. Journal of Pharmaceutical Health Services Research 2010; 1:9-14.
    19. Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report – Part IV. Value in Health 2010; 13(1):18-24.
    20. Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report – Part I. Value in Health 2010; 13(1):3-7.

 

2009

Return to top

    1. Mullins CD, Seal B, Blatt L. The Financial Implications of New Episodes of MDD for Treatment Resistant Versus Stable Depressed Individuals. Journal of Managed Care Medicine 2009; 12(4):5-12.
    2. Obeidat NA, Pradel FG, Zuckerman IZ, DeLisle S, Mullins CD. Outcomes of Irinotecan-Based Chemotherapy Regimens in Elderly Medicare Patients with Metastatic Colorectal Cancer. The American Journal of Geriatric Pharmacotherapy 2009; 7(6):343-54.
    3. Davidoff AJ, Rapp T, Onukwugha E, Zuckerman IH, Hanna N, Pandya N, Mullins CD. Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients: The Role of the Medical Oncologist Evaluation. Medical Care 2009; 47(12):1229-36.
    4. Margolis JM, Johnston SS, Chu BC, Onukwugha E, Hvidsten K, Alvir J, Rossi JG, Mullins CD. Effects of a Medicaid Prior Authorization Policy for Pregabalin. The American Journal of Managed Care 2009; 15(10):e95-102.
    5. Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD. Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. Journal of the American Geriatrics Society 2009; 57(8):1403-10.
    6. Pradel FG, Suwannaprom P, Mullins CD, Sadler J, Bartlett ST. Haemodialysis Patients’ Readiness to Pursue Live Donor Kidney Transplantation. Nephrology Dialysis Transplantation 2009; 24(4):1298-305.
    7. Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The Total Economic Burden of Overactive Bladder in the United States: A Disease-Specific Approach. The American Journal of Managed Care 2009; 15(4 suppl):S90-7.
    8. Mullins CD. New Perspectives on Overactive Bladder and Its Treatment: Introduction. The American Journal of Managed Care 2009; 15(4 suppl):S88-9.
    9. Blak BT, Mullins CD, Shaya FT, Simoni-Wastila L, Cooke CE, Weir MR. Prescribing Trends and Drug Budget Impact of the ARBS in the UK. Value in Health 2009; 12(2):302-8.

 

2008

Return to top

    1. Mullins CD, Rattinger GB, Kuznik A, Koren MJ. Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study. Clinical Therapeutics 2008; 30:2204-16.
    2. Pradel FG, Suwannaprom P, Mullins CD, Sadler J, Bartlett ST. Short-term impact of an educational program promoting live donor kidney transplantation in dialysis centers. Progress in Transplantation 2008; 18(4):263-72.
    3. Pradel FG, Jain R, Mullins CD, Vassalotti JA, Bartlett ST. A Survey of Nephrologists’ Views on Preemptive Transplantation. Clinical Journal of the American Society of Nephrology 2008; 3(6):1837-45.
    4. Wang J, Mullins CD, Zuckerman IH, Walker GD, Suda KJ, Yang Y, White-Means SI. Medical Expenditure Panel Survey: A Valuable Database for Studying Racial and Ethnic Disparities in Prescription Drug Use. Research in Social and Administrative Pharmacy 2008; 4(3):206-17.
    5. Balkrishnan R, Joish VN, Yang T, Jayawant SS, Mullins CD. The Economic Burden Associated with SSRI Treatment Failure in a Managed Care Population. Journal of Medical Economics 2008; 11(4):601-10.
    6. Mullins CD, Subedi PR, Turk F. Impact of Patient Sample on Costs of Events in Pharmacoeconomic Models. Expert Review of Pharmacoeconomics & Outcomes Research 2008; 8(5): 463-9.
    7. Rattinger GB, Jain R, Ju J, Mullins CD. Principles of Economics Crucial to Pharmacy Students’ Understanding of the Prescription Drug Market. American Journal of Pharmaceutical Education 2008; 72(3):61.
    8. Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Treatment Costs Associated with Community-Acquired Pneumonia by Community Level of Antimicrobial Resistance. Journal of Antimicrobial Chemotherapy 2008; 61(5):1162-8.
    9. Holtorf AP, Watkins JB, Mullins CD, Brixner D. Incorporating Observational Data into the Formulary Decision-Making Process – Summary of a Roundtable Discussion. Journal of Managed Care Pharmacy 2008; 14(3):302-8.
    10. Onukwugha E, Mullins CD, DeLisle S. Using Cost-Effectiveness Analysis to Sharpen Formulary Decision-Making: The Example of Tiotropium at the Veterans Affairs Health Care System. Value in Health 2008; 11(5):980-8.
    11. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of Discontinuation of Atypical Antipsychotic Agents in the Treatment of Schizophrenia. Schizophrenia Research 2008; 98(1-3):8-15.

 

2007

Return to top

    1. Palumbo FB, Mullins CD, Slagle AF, Rizer J. Policy Implications of Drug Importation. Clinical Therapeutics 2007; 29(12):2758-67.
    2. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis. Value in Health 2007; 10(5):336-47.
    3. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report. Value in Health 2007; 10(5):326-35.
    4. Mullins CD, Subedi PR, Healey PJ, Sanchez RJ. Economic Analysis of Triptan Therapy for Acute Migraine: A Medicaid Perspective. Pharmacotherapy 2007; 27(8):1092-1101.
    5. Wang J, Zuckerman IH, Miller NA, Shaya FT, Noel JM, Mullins CD. Utilizing New Prescription Drugs: Disparities among Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites. Health Services Research 2007; 42(4):1499-519.
    6. Mullins CD, Palumbo FB, Saba M. Formulary Tier Placement for Commonly Prescribed Branded Drugs: Benchmarking and Creation of a Preferred Placement Index. The American Journal of Managed Care 2007; 13(6, Part 2):377-84.
    7. Onukwugha E, Mullins CD. Racial Disparities in Hospital Discharge Disposition among Stroke Patients in Maryland. Medical Decision Making 2007; 27(3):233-42.
    8. Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT. New Diagnosis of Hypertension Among Celecoxib and Nonselective NSAID Users: A Population-Based Cohort Study. The Annals of Pharmacotherapy 2007; 41(6):937-43.
    9. Shaya FT, Samant N, Pradel F, Mullins CD, Scharf SM, Britt J. Health-related quality of life as a potential predictor in chronic obstructive lung disease patients. Expert Review of Pharmacoeconomics & Outcomes Research 2007; 7(2):129-35.
    10. Fink JC, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P, Seliger SL. Center Effects in Anemia Management of Dialysis Patients. Journal of the American Society of Nephrology 2007; 18(2):646-53.

 

2006

Return to top

    1. Wang J, Noel JM, Zuckerman IH, Miller NA, Shaya FT, Mullins CD. Disparities in Access to Essential New Prescription Drugs between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites. Medical Care Research and Review 2006; 63(6):742-63.
    2. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-Illness Studies: A Review of Current Methods. Pharmacoeconomics 2006; 24(9):869-90.
    3. Mullins CD, Pradel FG, Meng F, Blatt L, Bartlett ST. Relative Costs of Transplantation versus Dialysis. Journal of the Association for Academic Minority Physicians 2006; 17:36-43.
    4. Mullins CD, Lavallee DC, Pradel FG, DeVries AR, Caputo N. Health Plans’ Strategies for Managing Outpatient Specialty Pharmaceuticals. Health Affairs 2006; 25(5):1332-9.
    5. Mullins CD, Kuznik A, Shaya FT, Obeidat NA, Levine AR, Liu LZ, Wong W. Cost-Effectiveness Analysis of Linezolid Compared with Vancomycin for the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus. Clinical Therapeutics 2006; 28(8):1184-98.
    6. Chauncey D, Mullins CD, Tran BV, McNally D, McEwan RN. Medication access through patient assistance programs. American Journal of Health-System Pharmacy 2006; 63(13):1254-9.
    7. Shaya FT, El Khoury AC, Mullins CD, Du D, Skolasky R, Fatodu H, Garber H, Weir MR. Drug Therapy Persistence and Stroke Recurrence. The American Journal of Managed Care 2006; 12(6):313-9.
    8. Mullins CD, Shaya FT, Zito JM, Obeidat N, Naradzay J, Harrison DJ. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophrenia Research 2006; 83(2-3):277-284.
    9. Pradel FG, Subedi P, Varghese AA, Mullins CD, Weis KA. Does earlier headache response equate to earlier return to functioning in patients suffering from migraine? Cephalalgia 2006; 26(4):428-35.
    10. Mullins CD, Shaya FT, Meng F, Wang J, Bron MS. Comparison of First Refill Rates Among Users of Sertraline, Paroxetine, and Citalopram. Clinical Therapeutics 2006; 28(2):297-305.
    11. Baquet CR, Commiskey P, Mullins CD, Mishra SI. Recruitment and participation in clinical trials: Socio-demographic, rural/urban, and health care access predictors. Cancer Detection and Prevention 2006; 30(1):24-33.

 

2005

Return to top

    1. Perfetto EM, Weis KA, Mullins CD, Subedi P, Healey PJ. An Economic Evaluation of Triptan Products for Migraine. Value in Health 2005; 8(6):647-55.
    2. Benner JS, Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, O’Donnell JC. Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective. Value in Health 2005; 8(6):618-28.
    3. Mullins CD, Blatt L, Gbarayor CM, Yang HK, Baquet C. Health disparities: A barrier to high-quality care. American Journal of Health-System Pharmacy 2005; 62(18):1873-82.
    4. Mullins CD, DeVries AR, Hsu VD, Meng F, Palumbo FB. Variability and Growth in Spending For Outpatient Specialty Pharmaceuticals. Health Affairs 2005; 24(4):1117-27.
    5. Mullins CD, Subak LL. New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistency, and Treatment Costs. The American Journal of Managed Care 2005 11(4 suppl):S101-2.
    6. Shaya FT, Klaskala W, Mullins CD. Review of cost-effectiveness studies of pegylated therapies for hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 2005; 5(3):339-51.
    7. Shaya FT, Shin JY, Mullins CD, El Khoury AC, Garber H. Risk of Heart Failure with the Use of Thiazolidinediones within a Medicaid Population. Pharmacy and Therapeutics 2005; 30(5): 273-4, 279-81.
    8. Mullins CD, Weis KA, Perfetto EM, Subedi PR, Healey PJ. Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat. Journal of Managed Care Pharmacy 2005; 11(5):394-402.
    9. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, Switching, and Discontinuation Rates Among Patients Receiving Sertraline, Paroxetine, and Citalopram. Pharmacotherapy 2005; 25(5):660-7.
    10. Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Review of Pharmacoeconomics & Outcomes Research 2005; 5(1):65-79.
    11. Shaya FT, Shin JY, Mullins CD, Fatodu HO, Gu A, Saunders E. Medicaid Managed Care: Disparities in the Use of Thiazolidinediones Compared with Metformin. Journal of the National Medical Association 2005; 97(4):493-7.
    12. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD. Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population. Archives of Internal Medicine 2005; 165(2):181-6.
    13. Mullins CD, Thomas SK, Cooke J. The Impact of Pharmacogenomics on the Cost-Effectiveness Ratio in Principles of Pharmacoeconomics, 3rd edition 2005; Chapter 10:237-58, Cincinnati, OH: Harvey Whitney Books Company.

 

2004

Return to top

    1. Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet C. Economic Disparities in Treatment Costs among Ambulatory Medicaid Cancer Patients. Journal of the National Medical Association 2004; 96(12):1565-74.
    2. Zuckerman IH, Menis M, McNally DL, Layne BA, Mullins CD. Intervention for Decreasing Excessive Acetaminophen Use In Pennsylvania Medicaid Recipients. American Journal of Health-System Pharmacy 2004; 61(22):2410-4.
    3. Mullins CD, Cohen LA, Magder LS, Manski RJ. Medicaid Coverage and Utilization of Adult Dental Services. Journal of Health Care for the Poor and Underserved 2004; 15(4):672-87.
    4. Pradel FG, Palumbo FB, Flowers L, Mullins CD, Haines ST, Roffman DS. White Paper: Value of Specialty Certification in Pharmacy. Journal of the American Pharmacists Association 2004; 44(5):612-20.
    5. Mullins CD, Sikirica M, Seneviratne V, Ahn J, Akhras KS. Comparisons of Hypertension-Related Costs from Multinational Clinical Studies. Pharmacoeconomics 2004; 22(15):1001-1014.
    6. Shaya FT, Blume S, Mullins CD. Prescription Drug Spending Tends For The Privately Insured in Maryland, 2000-2001. Health Affairs 2004; 23(5):226-32.
    7. Zuckerman IH, Weiss SR, McNally D, Layne B, Mullins CD, Wang J. Impact of an Educational Intervention for Secondary Prevention of Myocardial Infarction on Medicaid Drug Use and Cost. The American Journal of Managed Care 2004; 10(7):493-500.
    8. Mullins CD, Cooke JL, Wang J, Shaya FT, Hsu VD, Brooks S. Disparities in Prevalence Rates for Lung, Colorectal, Breast, and Prostate Cancers in Medicaid. Journal of the National Medical Association 2004; 96(6):809-16.
    9. Grant WC, Yoder DM, Mullins CD. Threshold denial rates in prior authorization prescription programs. Expert Review of Pharmacoeconomics & Outcomes Research 2004; 4(2):165-9.
    10. Mullins CD, Wang J, Cooke JL, Blatt L, Baquet CR. Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer: A Pilot Study. Pharmacoeconomics 2004; 22(5):285-91.
    11. Mullins CD, Shaya FT, Flowers LR, Saunders E, Johnson W, Wong W. Health Care Cost of Analgesic Use in Hypertensive Patients. Clinical Therapeutics 2004; 26(2):285-93.

 

2003

Return to top

    1. Cohen LA, Magder LS, Manski RJ, Mullins CD. Hospital Admissions Associated with Nontraumatic Dental Emergencies in a Medicaid Population. American Journal of Emergency Medicine 2003; 21(7):540-4.
    2. Mullins CD, Wang J, Stoller JK. Major Components of the Direct Medical Costs of Alpha 1-Antitrypsin Deficiency. Chest 2003; 124(3):826-31.
    3. Mullins CD, Flowers LR. Evaluating Economic Outcomes Literature in Pharmacoeconomics and Outcomes: Applications for Patient Care, 2nd edition 2003; Chapter 14:246-65, Kansas City, MO: American College of Clinical Pharmacy.
    4. Cohen LA, Manski RJ, Magder LS, Mullins CD. A Medicaid Population’s Use of Physicians’ Offices for Dental Problems. American Journal of Public Health 2003; 93(8):1297-1301.
    5. Pradel FG, Mullins CD, Bartlett ST. Exploring Donors’ and Recipients’ Attitudes About Living Donor Kidney Transplantation. Progress in Transplantation 2003; 13(3):203-10.
    6. Mullins CD, Thomas SK, Pradel FG, Bartlett ST. The Economic Impact of Laparoscopic Living-Donor Nephrectomy on Kidney Transplantation. Transplantation 2003; 75(9):1505-12.
    7. Mullins CD. Response to Torrance et al. [Osteoarthritis and Cartilage 2002; 10:518-27]. Letter to the editor. Osteoarthritis and Cartilage 2003; 11:377-8.
    8. Pradel FG, Limcangco MR, Mullins CD, Bartlett ST. Patients’ Attitudes About Living Donor Transplantation and Living Donor Nephrectomy. American Journal of Kidney Diseases 2003 41(4):849-58.
    9. Mullins CD, Ndiritu EM, Yoder DM, Shaya FT, Taylor TA. Impact of the Fourth Hurdle on the International Pharmaceutical Industry. Expert Review of Pharmacoeconomics & Outcomes Research 2003; 3(2):169-177.
    10. Mullins CD, Ohsfeldt RL. Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy. Journal of Managed Care Pharmacy 2003; 9(2):150-8.
    11. Merchant S, Mullins CD, Shih YT. Factors Associated with Hospitalization Costs for Patients with Community-Acquired Pneumonia Clinical Therapeutics 2003; 25(2):593-610.

 

2002

Return to top

    1. Palumbo FB, Mullins CD. The Development of Direct-to-Consumer Prescription Drug Advertising Regulation. Food and Drug Law Journal 2002; 57(3):423-43.
    2. Thomas SK, Brooks SE, Mullins CD, Baquet CR, Merchant S. Use of ICD-9 Coding as a Proxy for Stage of Disease in Lung Cancer. Pharmacoepidemiology and Drug Safety 2002; 11(8):709-13.
    3. Brooks SE, Ahn J, Mullins CD, Baquet CR. Resources and Use of the Intensive Care Unit in Patients Who Undergo Surgery for Ovarian Carcinoma. Cancer 2002; 95(7):1457-62.
    4. Shaya FT, Mullins CD, Wong W. Incidence versus prevalence modeling in pharmacoeconomics. Expert Review of Pharmacoeconomics & Outcomes Research 2002; 2(5):435-42.
    5. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation Rates of Topical Glaucoma Medications in a Managed Care Population. The American Journal of Managed Care 2002 8(10 suppl):S271-7.
    6. Mullins CD, Philbeck TE, Schroeder WJ, Thomas SK. Cost Effectiveness of Kinetic Therapy in Preventing Nosocomial Lower Respiratory Tract Infections in Patients Suffering from Trauma. Managed Care Interface 2002; 15(8):35-40.
    7. Mullins CD, Blak BT, Akhras KS. Comparing Cost-Effectiveness Analyses of Anti-Hypertensive Drug Therapy for Decision Making: Mission Impossible? Value in Health 2002; 5(4):359-71.
    8. Cohen LA, Manski RJ, Magder LS, Mullins CD. Dental visits to hospital emergency departments by adults receiving Medicaid: Assessing their use. Journal of the American Dental Association 2002; 133:715-24.
    9. Baquet CR, Hammond C, Commiskey P, Brooks S, Mullins CD. Health Disparities Research – A Model for Conducting Research on Cancer Disparities: Characterization and Reduction. Journal of the Association for Academic Minority Physicians 2002; 13(2):33-40.
    10. Mullins CD, Blatt L, Wang J. Societal implications of the pharmacoeconomics of Alpha 1-antitrypsin deficiency. Expert Review of Pharmacoeconomics & Outcomes Research 2002; 2(3):243-9.
    11. Brooks SE, Mullins CD, Guo C, Chen TT, Gardner JF, Baquet CR. Resource Utilization for Patients Undergoing Hysterectomy with or without Lymph Node Dissection for Endometrial Cancer. Gynecologic Oncology 2002; 85(2):242-9.
    12. Mullins CD, Wang J. Pharmacy Benefit Management: Enhancing the Applicability of Pharmacoeconomics for Optimal Decision Making. Pharmacoeconomics 2002; 20(1):9-21.

 

2001

Return to top

    1. Mullins CD, Lyons BM, Ahn J. Pharmaceutical Market Impact of the Early 1990’s Health Care Debate. Journal of Research in Pharmaceutical Economics 2001; 11(2):1-22.
    2. Mullins CD. The Economics of Lipid Management. Managed Care 2001; 10(11 Suppl):S17-18.
    3. Perfetto EM, Mullins CD, Subedi P, Li-McLeod J. Selection of Clinical, Patient-Reported, and Economic End Points in Acute Exacerbation of Chronic Bronchitis. Clinical Therapeutics 2001; 23(10):1747-72.
    4. Mullins CD, Wang J, Palumbo FB, Stuart B. The Impact of Pipeline Drugs on Drug Spending Growth. Health Affairs 2001; 20(5):210-215.
    5. Brooks SE, Ahn J, Mullins CD, Baquet CR, D’Andrea A. Health Care Cost and Utilization Project Analysis of Comorbid Illness and Complications for Patients Undergoing Hysterectomy for Endometrial Cancer. Cancer 2001; 92(4):950-8.
    6. Mullins CD, Huang X, Merchant S, Stoller JK. The Direct Medical Costs of Alpha 1-Antitrypsin Deficiency. Chest 2001; 119(3):745-52.
    7. Mullins CD, Thomas SK, Roffman DS. Pharmaceutical Restrictions: Possible Effect on Patient/Physician Buy-in of Disease Management Programs. Disease Management & Health Outcomes 2001; 9(2):69-74.
    8. Kulsomboon V, Palumbo FB, Mullins CD. Criteria to Request Pharmacoeconomic Data and Data Sources for Hospital Formulary Decisions. Drug Information Journal 2001; 35(1):231-240.
    9. Mullins CD, Merchant S. Guidelines and Information Requirements in Introduction to Applied Pharmacoeconomics 2001; Chapter 11:229-261, New York: McGraw-Hill.

 

2000

Return to top

    1. Mullins CD, Whitelaw G, Cooke JL, Beck EJ. Indirect Cost of HIV Infection in England. Clinical Therapeutics 2000; 22(11):1333-45.
    2. Brooks SE, Chen TT, Ghosh A, Mullins CD, Gardner JF, Baquet CR. Cervical Cancer Outcomes Analysis: Impact of Age, Race and Comorbid Illness on Hospitalizations for Invasive Carcinoma of the Cervix. Gynecologic Oncology 2000; 79(1):107-15.
    3. Reed SO, Mullins CD, Magder LS. Cost Effectiveness of Abciximab During Routine Medical Practice. Pharmacoeconomics 2000; 18(3):265-74.
    4. Luchette FA, Barrie PS, Oswanski MF, Spain DA, Mullins CD, Palumbo F, Pasquale MD. Practice Management Guidelines for Prophylactic Antibiotic Use in Tube Thoracostomy for Traumatic Hemopneumothorax. The Journal of Trauma 2000; 48(4):753-7.
    5. Luchette FA, Borzotta AP, Croce MA, O’Neill PA, Whittmann DH, Mullins CD, Palumbo F, Pasquale MD. Practice Management Guidelines for Prophylactic Antibiotic Use in Penetrating Abdominal Trauma. The Journal of Trauma 2000; 48(3):508-18.

 

1999

Return to top

    1. Mullins CD. An Overview of Cancer Economics. The American Journal of Managed Care 1999; 5(6 suppl):S371-S376.
    2. Amin SP, Mullins CD, Duncan BS and Blandford L. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. American Journal of Health-System Pharmacy 1999; 56(15):1515-20.
    3. Weidle P, Bradley L, Gallina J, Mullins CD, Thorn D, and Siegel LP. Pharmaceutical Care Intervention Documentation Program and Related Cost Savings at a University Hospital. Hospital Pharmacy 1999; 34(1):43-52.

 

1998

Return to top

    1. Mullins CD and Ogilvie SD. Emerging Standardization in Pharmacoeconomics. Clinical Therapeutics 1998; 20(6):1194-1202.
    2. Reed SD, Mullins CD, Roffman DS and Mays DA. Difficulties in applying clinical trial information to the practice setting: Case of a high-cost drug. American Journal of Health-System Pharmacy 1998; 55(22):2409-14.
    3. Mullins CD and Palumbo FB. Maintaining Public Assistance Data in the Managed Care Era. SGIM (Society of General Internal Medicine) Forum 1998; 21(3):5,10.

 

1997

Return to top

    1. Mullins CD, Cooke CE, and Cooke JL. Applications of Pharmacoeconomics for Managed Care Pharmacy. Journal of Managed Care Pharmacy 1997; 3(6):720-726.
    2. Grabowski HG and Mullins CD. Pharmacy Benefit Management, Cost-Effectiveness Analysis, and Drug Formulary Decisions. Social Science & Medicine 1997; 45(4):535-544.
    3. Mullins CD, Morris LS, Perfetto EM and Ogilvie SD. Pharmacoeconomics of NSAIDs: Beyond Bleeds. Journal of Managed Care Pharmacy 1997; 3(4):425-430.
    4. Palumbo FB and Mullins CD. Quality-of-care data from managed care organizations. Letter to the editor. New England Journal of Medicine 1997; 336(6):443-444.

 

1996

Return to top

    1. Mullins CD. Price and Welfare Implications of a Medicare Pharmaceutical Rebate. New York Health Sciences Journal 1996; 1(4):243-255.
    2. Mullins CD. Most-Favored-Customer Protection and Medicaid Rebates under OBRA 1990. Journal of Research in Pharmaceutical Economics 1996; 7(3):49-63.
    3. Mullins CD and Weisman ES. A Simplified Approach to Teaching Markov Models. American Journal of Pharmaceutical Education Spring 1996; 60(1):42-7.
    4. Mullins CD, Baldwin R and Perfetto EM. What Are Outcomes? Journal of the American Pharmaceutical Association January 1996; NS36(1):39-49.

 

1995

Return to top

    1. Mullins CD. Toward an Understanding of Pharmaceutical Pricing Strategies Through the Use of Simple Game Theoretic Models. Journal of Research in Pharmaceutical Economics 1995; 6(3):1-14. (Reprinted in Smith, MC, ed. Studies in Pharmaceutical Economics. New York: Pharmaceutical Products Press, 1996.)
    2. Hartzema AG and Mullins CD. Pharmaceutical Chartbook. New York: Pharmaceutical Products Press, 1995.

 

1994

Return to top

  1. Mullins CD. Combining the Principles of Epidemiology and Economics. American Journal of Pharmaceutical Education Winter 1994; 58[4]:427-430.
  2. Mullins CD. Drug Firm-Mail-Order Mergers: Marriages of Convenience? American Pharmacy August 1994; NS34(8):38-42.